Australie - anglais - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - methoxy polyethylene glycol-epoetin beta, quantity: 0.12 mg - injection, solution - excipient ingredients: sodium sulfate; monobasic sodium phosphate monohydrate; poloxamer; methionine; mannitol; water for injections - mircera is indicated for the treatment of anaemia associated with chronic kidney disease (ckd).

Australie - anglais - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - methoxy polyethylene glycol-epoetin beta, quantity: 0.1 mg - injection, solution - excipient ingredients: sodium sulfate; poloxamer; monobasic sodium phosphate monohydrate; mannitol; methionine; water for injections - mircera is indicated for the treatment of anaemia associated with chronic kidney disease (ckd).

Australie - anglais - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - methoxy polyethylene glycol-epoetin beta, quantity: 0.2 mg - injection, solution - excipient ingredients: poloxamer; sodium sulfate; methionine; mannitol; monobasic sodium phosphate monohydrate; water for injections - mircera is indicated for the treatment of anaemia associated with chronic kidney disease (ckd).

Australie - anglais - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - methoxy polyethylene glycol-epoetin beta, quantity: 0.36 mg - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium sulfate; poloxamer; mannitol; methionine; water for injections - mircera is indicated for the treatment of anaemia associated with chronic kidney disease (ckd).

Australie - anglais - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - methoxy polyethylene glycol-epoetin beta, quantity: 0.075 mg - injection, solution - excipient ingredients: mannitol; methionine; monobasic sodium phosphate monohydrate; poloxamer; sodium sulfate; water for injections - mircera is indicated for the treatment of anaemia associated with chronic kidney disease (ckd).

Australie - anglais - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atorvastatin calcium propylene glycol solvate -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atorvastatin calcium propylene glycol solvate -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atorvastatin calcium propylene glycol solvate -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atorvastatin calcium propylene glycol solvate -

États-Unis - anglais - NLM (National Library of Medicine)

strides pharma science limited - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium sulfate anhydrous (unii: 36kcs0r750) (sodium sulfate anhydrous - unii:36kcs0r750), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chlorate (unii: h35ks68ee7) (potassium cation - unii:295o53k152, chlorate ion - unii:08z8093742) - polyethylene glycol 3350 and electrolytes for oral solution is indicated for bowel cleansing prior to colonoscopy and barium enema x-ray examination in adults polyethylene glycol 3350 and electrolytes for oral solution, is contraindicated in the following conditions: -   gastrointestinal (gi) obstruction [see warnings and precautions (5.6)] -   bowel perforation [see warnings and precautions (5.6)] -   toxic colitis or toxic megacolon -   gastric retention -   ileus -   hypersensitivity to any component of polyethylene glycol 3350 and electrolytes for oral solution [see warnings and precautions (5.8)] animal reproduction studies have not been conducted with polyethylene glycol 3350 and electrolytes for oral solution. it is also not known whether polyethylene glycol 3350 and electrolytes for oral solution, can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. polyethylene glycol 3350 and electrolytes for oral solution, should be given to a pregnant woman only if clearl